Systemic therapy in early stage NSCLC. Disclosures
|
|
- Annis Merritt
- 6 years ago
- Views:
Transcription
1 Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany Disclosures Consultancy: Hoffmann-La Roche, Pfizer, Eli Lilly, Merck-Serono, Novartis, Amgen, Boehringer Ingelheim, AstraZeneca Speaking: Hoffmann-La Roche, Eli Lilly, Merck- Serono, AstraZeneca Grant support: Merck-Serono, Sanofi-Aventis, Eli Lilly Travel Support: Hoffmann-La Roche, Merck- Serono, Eli Lilly, AstraZeneca 1
2 Chemotherapy in early stage NSCLC Stage I III operable Chemotherapy adjuvant / postoperative Stage I-III III inoperable ChemoRadiotherapy sequential Chemotherapy neoadjuvant/ preoperative ChemoRadiotherapy concomitant Expected outcome following surgical resection in operable NSCLC Pisters and Le Chevallier, J Clin Oncol 23, ,
3 Neo-adjuvant chemotherapy Adjuvant chemotherapy ESMO - clinical practice guidelines Neo-adjuvant cisplatin-based chemotherapy is recommended in stage IIIA/N2 - radically resected NSCLC Crino et al. Ann Oncol 21 (Suppl 5), ,
4 Early NSCLC: advantages of neoadjuvant chemotherapy Early treatment t t of distant t micrometatstases t t Local-regional cytoreduction preoperatively Better patient acceptance Better tolerability and dose delivery Pisters et al. J Thor Cardiovasc Surg 119, 429,2000 Early NSCLC neoadjuvant chemotherapy (phase II) EORTC EORTC EORTC SAKK 4 Tampa 5 Cis Carbo / Cis / Cis / Pemetrexed/ /Gemcitabine Paclitaxel Docetaxel Docetaxel Gemcitabine Pts CR 6.3% - 2.5% 8% 2% PR 63.8% 59% 42.5% 58% 31% SD 6.3% 18% 35% 25% 56% PD 4.2% 23% 2.5% 9% 7% 1 van Zandwijk et al J Clin Oncol 18, , 2000; 2 O Brien et al Proc ASCO 18 (Abstr. 1898), 1999; 3 Betticher et al J Clin Oncol 21, , 2003; 4 Bisma et al EJC 42, ,2006; 5 Bepler et al J Clin Oncol 24, (18S), 396 (Abstr. 7129),
5 NSCLC - neoadjuvant chemotherapy: metaanalysis surgery/ct vs. surgery alone Gilligan et al. Lancet 369: , 2007 Burdett et al. J Thorac Oncol 1: , 2006 Chemotherapy benefit in early NSCLC Neoadjuvant chemotherapy: HR 0.88 (95%CI: ) corresponding with an absolute survival benefit of 5.4 % at 5 years Gilligan et al. Lancet 369: ,
6 Neo-adjuvant chemotherapy Adjuvant chemotherapy ESMO - clinical practice guidelines Adjuvant chemotherapy is recommended in stage II - III radically resected NSCLC Crino et al. Ann Oncol 21 (Suppl 5), ,
7 NSCLC- adjuvant chemotherapy: summary of recent trials N HR (95%CI) Stage Year BMJ meta ( ) I-III 1995 IALT ( ) I-III 2004 ALPI ( ) I-IIIA 2003 ECOG ( ) II-IIIA 2000 BLT ( ) I-III 2004 BR ( ) II 2005 ANITA ( ) IB-IIIA 2006 BMJ meta update ( ) I-III 2007 French meta ( ) I-IIIA 2007 CALGB ( ) IB 2008 LACE meta ( ) IA-IIIB 2008 Early NSCLC adjuvant chemotherapy (LACE- metaanalysis): effect on OS and DFS HR: 0.89; 95% CI: HR: 0.84; 95% CI: ; 0.96; p= ; 0.91; p< % reduction in risk of death; absolute benefit of 5.4% at 5 years 16% reduction in risk of disease progression; absolute benefit of 5.8% at 5 years Pignon et al J Clin Oncol 26: ,
8 NSCLC adjuvant chemotherapy: metaanalyses Adding CT to surgery: absolute survival increase of 4% at 5 years Adding CT to surgery/rt: absolute survival increase of 4% at 5 years NSCLC-metaanalysis collaborative group: Lancet 375, , 2010 Early NSCLC - adjuvant chemotherapy: LACE-metaanalysis Efficacy by stage OS Pts. HR [95% CI] Stage IA [0.95;2.06] Stage IB [0.78;1.10] Stage II [0.73;0.95] Stage III [0.73;0.95] Pignon et al J Clin Oncol 26, ,
9 Elderly patients and adjuvant chemotherapy NSCLC adjuvant chemotherapy in the elderly: SEER database/ Ontario cancer registry Platinum-based chemotherapy improves survival (with or without t RT) Chemotherapy did not improve survival in pts. 80 years Tolerability appeared similar between pts. <70 years versus 70 years Chemotherapy was associated with increased SAE Wisnivesky et al, BMJ 14; 343: d4013. doi: /bmj.d4013, 2011 Cuffe et al. J Clin Oncol 30, ,
10 Type / duration of adjuvant chemotherapy NSCLC - adjuvant chemotherapy: type / duration in randomized clinical trials Study Pts. Type of CT Author (no. of cycles) ALPI 474 Cisplatin-based (3) Scagliotti (2003) BLT 192 Cisplatin-based (3) Waller (2003) IALT 932 Cisplatin-based (3/4) Olaussen (2004) CALGB Carboplatin/Tax (4) Strauss (2008) ANITA 367 Cisplatin/Vin (4) Douillard (2006) BR Cisplatin/Vin (4) Winton (2005) 10
11 Chemotherapy benefit in early NSCLC Adjuvant chemotherapy: HR 0.89 (95%CI: ) corresponding with an absolute survival benefit of 5% at 5 years Pignon et al J Clin Oncol 26: , 2008 Compliance and adjuvant chemotherapy 11
12 NSCLC - adjuvant chemotherapy : compliance in randomized clinical trials Study Pts. Compliance Author ALPI % Scagliotti (2003) BLT % Waller (2003) IALT % Olaussen (2004) CALGB % Strauss (2008) ANITA % Douillard (2006) BR % Winton (2005) Adjuvant chemotherapy followed by adjuvant radiotherapy 12
13 Early NSCLC adjuvant CT / RT (ANITA): survival according to lymph node status Best survival in stage III/N2 for adjuvant CT followed by RT Douillard et al. Lancet Oncol 7: , 2006 NSCLC - adjuvant radiotherapy: Cancer Care Ontario/ASCO - Guidelines Pisters et al. J Clin Oncol 25: ,
14 Pemetrexed and adjuvant chemotherapy NSCLC - adjuvant chemotherapy (TREAT - phase II): Cis/Pemetrexed vs. Cis/Vinorelbine Cis/Pemetrexed is similar effective Cis/Pemetrexed less toxic Cis/Pemetrexed with superior dose delivery Cis/Pemetrexed with higher dose density Kreuter et al. J Clin Oncol 29 (suppl 15), 453, (abstr 7002),
15 NSCLC: adjuvant chemotherapy - Pemetrexed containing regimens/trials - Japan UMIN Phase III China NCT Phase II USA ECOG1505- NCT Phase III Carbo- Gem/Pac/Pem Platin- Pem/Vin Cis- Vin/Doc/Gem/Pem +/- Killer cells Dentritic cells +/- Killer cells (CIK) N=800 Stage II-IV resected N=222 Stage IB-IIIA +/- Bevacizumab N=1500 Stage IB-IIIA Pharmocogenomics and adjuvant chemotherapy 15
16 NSCLC (ITACA phase III): International Tailored (ERCC1/TS) adjuvant chemotherapy High Profile 4 Taxane PE: overall survival High TS Control* Pemetrexed completely resected stage II-IIIA ECOG 0/1 n=700 *Investigators choice of a platinum-based doublet ERCC1 Low Low Profile 3 High TS Low Profile 2 Profile 1 ERCC1: Excision repair cross complementing group 1 gene TS: Thymidilate Synthase Control* Cis/Gem Control* Cis/Pem Control* NSCLC - chemotherapy: potential predictive molecular markers for response Gene Abnormality Drug Response p53 Mutation Multiple K-ras Mutation Multiple tubulin Increased Isotype 3 Taxanes RRM 1 Increased Expression Gemcitabine ERCC 1 Increased Expression Platinum TS Increased Expression Antifolates EGFR Mutation EGFR-TKI BRCA 1 Increased Expression Anti - microtubulins BRCA 1 Increased Expression Platinum 16
17 NSCLC (TASTE trial): tailored (ERCC1, EGFR mut.) adjuvant Therapy TAilored Post-Surgical Therapy in Early Stage NSCLC Phase II/III Stage II-IIIA complete resection, EGFR mut ERCC1 Control arm EGFR WT EGFR mutant NCT Cis/Pem ERCC1 high ERCC1 low Erlotinib No treatment Cis/Pem NSCLC (BR19): adjuvant therapy by Gefitinib - overall survival Overall population Sensitizing i mutation ti Placebo Gefitinib Percentage at Risk 0 Placebo 40 Gefitinib Time (Years) Goss et al. J Clin Oncol 28 (suppl 15), 516 (abstr 7005),
18 NSCLC (SELECT): tailored (EGFR mut.) adjuvant therapy by Erlotinib Phase II Stadium II-IIIA nach kompletter Resektion EGFR- Mutation + Erlotinib 150 mg/d 2 Jahre N=36: 2-years DFS 94% (95% CI, 80%-99%) Expansion to 100 pts. to permit analysis by stage Pennell et al. J Clin Oncol 29 (Suppl, Abstr. TPS209) 2011 Neal et al. J Clin Oncol 30 (Suppl, Abstr. 7010) 2012 NSCLC (WJOG6410L): tailored (EGFR mut.) adjuvant therapy - Gefitinib vs. CT WJOG 6410L, Impact study 18
19 NSCLC (SWOG 0720): tailored (ERCC1, RRM1) adjuvant Chemotherapy Phase II Stage IA- IB complete resection, RRM1 ERCC1 ERCC1 > 65 RRM1 > 40 ERCC1 < 65 RRM1 < 40 No treatment Cis/Gem NCT NSCLC (SCAT): tailored (BRCA1) adjuvant chemotherapy Spanish customized adjuvant treatment according BRCA1 Phase III Stage II-IIIA complete resection mrna BRCA1 level High level Taxane No Platinum Low level Platinum based CT Massuti J Clin Oncol 29 (Suppl, Abstr. TPS208) 2011 Trials in progress Poster 19
20 Systemic therapy in early stage NSCLC Adjuvant chemotherapy is recommended in stage II - III radically resected NSCLC Cisplatin-based chemotherapy improves OS and DFS Benefit is greatest in stage II and III, and in PS 0-1 There is no significant interaction between CT and type of surgery, histology, age, gender, or planned RT Current trials investigate the role of pharmacogenomics Neo-adjuvant cisplatin-based chemotherapy is recommended in stage IIIA/N2- radically resected NSCLC Benefit similar to adjuvant therapy 20
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationOptimal Application of Adjuvant Therapy in NSCLC
Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo
More informationSlide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3
Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationState of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationAdjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
More informationERCC-1 1 and response to chemotherapy. Jean-Charles SORIA, MD, PhD Institut Gustave Roussy
ERCC-1 1 and response to chemotherapy 1 Jean-Charles SORIA, MD, PhD Institut Gustave Roussy Cancer and Chemotherapy: the exemple of Lung Cancer 2 50 CT + supportive care 40 Surgery ± CT Patients (%) 30
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationCHEMIOTERAPIA ADIUVANTE NEL NSCLC Dr. RITA CHIARI Oncologia Medica - Perugia.
! CHEMIOTERAPIA ADIUVANTE NEL NSCLC Dr. RITA CHIARI Oncologia Medica - Perugia ritachiar@gmail.com ! DICHIARAZIONE Relatore: RITA CHIARI Come da nuova regolamentazione della Commissione Nazionale per la
More informationDebate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationIndividualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers
Review Individualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers Norihiko Ikeda, MD, Seisuke Nagase, MD, and Tatsuo Ohira, MD Several prospective randomized trials
More informationThe 5-year survival in patients with resected NSCLC ranges
SHIRISH M. GADGEEL Role of Chemotherapy and Targeted Therapy in Early-Stage Non Small Cell Lung Cancer Shirish M. Gadgeel, MD OVERVIEW On the basis of several randomized trials and meta-analyses, adjuvant
More informationAdjuvant therapy of NSCLC: where to go from here?
SAMO Winter Workshop on Chest Tumours Adjuvant therapy of NSCLC: where to go from here? J Vansteenkiste Dept Pulmonology Leuven Lung Cancer Group > adjuvant therapy ± 1,200,000 lung cancers worldwide >80%
More informationThe Evolving Role of Adjuvant Therapies
Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationAdjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationSlide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years
Slide 1 Individualized Therapy in Lung Cancer : Where are we in 2011? Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Slide 2 Notable
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationTreatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationIndividualized therapy in lung cancer Where are we in 2012?
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Individualized therapy in lung cancer Where are we in 2012? Giorgio V. Scagliotti University of Torino Professor of Medical Oncology Department of Oncology
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationAdjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
Editorial Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine Peng Shen 1, Wenzhao Zhong 2 1 Department of Oncology, Nanfang Hospital, Southern Medical
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationAdjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC)
Review Article Adjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC) Ying Liang 1, Heather A. Wakelee 2 1 Department of Medical Oncology, Cancer Center, Sun Yat-sen
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationCME Information. without targetable tumor mutations. ResearchToPractice.com/IASLCNSCLC15 1
Beyond the Guidelines Clinical Investigators Provide Their Perspectives on Current Treatment Strategies and Ongoing Research in the Management of Non-Small Cell Lung Cancer without Targetable Tumor Mutations
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Valencia May 2018 State of the art: Standards of care in preoperative treatment for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures:
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationNeo-adjuvant chemotherapy in NSCLC
SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationAdjuvant Chemotherapy for Non-small Cell Lung Cancer
PISA SYMPOSIUM Adjuvant Chemotherapy for Non-small Cell Lung Cancer Emilio Bria, MD, Federica Cuppone, MD, Fabiana Letizia Cecere, MD, Michele Milella, MD, Cecilia Nisticò, MD, Francesco Cognetti, MD,
More informationSelection of systemic therapy in Advanced NSCLC based on biological factors. State of the Art
Selection of systemic therapy in Advanced NSCLC based on biological factors State of the Art Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationCâncer de Pulmão Não Pequenas Células
Câncer de Pulmão Não Pequenas Células Carboplatina + Paclitaxel Paclitaxel: 200mg/m 2 IV D1 Carboplatina: AUC 6 IV D1 a cada 21 dias X 4 ciclos Ref. (1) Vinorelbina + Cisplatina Vinorelbina: 25mg/m 2 IV
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationHow to deal with patients with isolated peritoneal metastases
ESMO Preceptorship Programme Colorectal Valencia 18-19 May 2018 Michel DUCREUX, MD, PhD Gustave Roussy Cancer Centre, Grand Paris, FRANCE How to deal with patients with isolated peritoneal metastases DISCLOSURE
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationAdjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?
Editorial Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough? Giandomenico Roviello 1, Marco Imperatori 1, Michele Aieta 1, Francesco Sollitto 2, Matteo Landriscina
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationJ. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer J. C.-H. Yang 1, L.V. Sequist
More informationAre we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?
Review Article Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? Bartomeu Massuti 1, Jose Miguel Sanchez 2, Florentino Hernando-Trancho
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationCooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D.
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery, Kanagawa
More informationNEJ, Sendai North East Japan. TCOG, Tokyo Tokyo Clinical Oncology G.
Slide 1 Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery,
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More information